News & Events
-
September 7, 2012
C-Path, CDISC launch “breakthrough” tool for TB drug development
A “breakthrough” tool that standardises reporting of research data in the development of drug regimens to combat tuberculosis (TB) has been launched by the US-based Critical Path Institute (C-Path) and Clinical Data Interchange Standards Consortium (CDISC).... -
May 1, 2012
Renewed Focus on Tuberculosis Holds Promise for New Treatments
FDA approved rifampin for the treatment of tuberculosis (TB) in 1971, the same year Intel Corporation invented the first microprocessor. Since then, advances in computer technology have revolutionized the way people live and work. But no additional medications have been approved by FDA for the treatment of Mycobacterium tuberculosis infection—a problem that federal officials and...... -
March 19, 2012
Critical Path Institute Honors World Tuberculosis Day 2012
Tuberculosis (TB) is often thought to be a disease of the past. The reality: Because no new therapies for TB have been developed in the past 50 years and treatment is long and complex, TB continues to kill 1.4 million people a year- someone every 20 seconds. Additionally, drug resistant forms of TB are an...... -
November 9, 2011
CPTR Yields Progress: New Five-Way Agreement Among Pharmas and NGOs will Speed Development of TB Drug Combinations
The Critical Path to TB Drug Regimens (CPTR) today announced an innovative agreement between AstraZeneca, Sanofi, Tibotec, TB Alliance, and the World Health Organization to share information on tuberculosis (TB) compounds within their respective drug pipelines to quickly identify and work together to develop the most promising TB drug regimen, regardless of sponsor. Previously, development...... -
April 29, 2011
Critical Path Institute Announces Expansion of Regulatory Science Consortium For Tuberculosis
Critical Path Institute is proud to announce that the Regulatory Science Consortium, an arm of the Critical Path to TB Drug Regimens (CPTR), has added ten new member organizations that include over 100 participants in five workgroups....